



Cite this: *Lab Chip*, 2018, 18, 179

A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement†

Andreas R. Thomsen,^{id} *^{abc} Christine Aldrian,^{abc} Peter Bronsert,^{id} ^{bcd} Yi Thomann,^f Norbert Nanko,^{ac} Nicolas Melin,^g Gerta Rücker,^{id} ^{ch} Marie Follo,^{id} ^{ci} Anca L. Grosu,^{id} ^{abc} Gabriele Niedermann,^{id} ^{abc} Paul G. Layer,^j Anja Heslich,^{id} ^k and Per G. Lund^{id} *^{ac}

Multicellular spheroids represent a well-established 3D model to study healthy and diseased cells *in vitro*. The use of conventional 3D cell culture platforms for the generation of multicellular spheroids is limited to cell types that easily self-assemble into spheroids because less adhesive cells fail to form stable aggregates. A high-precision micromoulding technique developed in our laboratory produces deep conical agarose microwell arrays that allow the cultivation of uniform multicellular aggregates, irrespective of the spheroid formation capacity of the cells. Such hydrogel arrays warrant a steady nutrient supply for several weeks, permit live volumetric measurements to monitor cell growth, enable immunohistochemical staining, fluorescence-based microscopy, and facilitate immediate harvesting of cell aggregates. This system also allows co-cultures of two distinct cell types either in direct cell–cell contact or at a distance as the hydrogel permits diffusion of soluble compounds. Notably, we show that co-culture of a breast cancer cell line with bone marrow stromal cells enhances 3D growth of the cancer cells in this system.

Received 6th August 2017,
Accepted 3rd October 2017

DOI: 10.1039/c7lc00832e

rsc.li/loc

Introduction

2D cell cultures are increasingly being replaced by 3D cultures, thereby approaching more *in vivo*-like conditions.¹ Traditional cell culture is based on cell adhesion to surfaces, which does not reflect the physiological situation in tissues

including cancer. A scaffold that supports cell adhesion represents a defined material which replaces the extracellular matrix (ECM) to approach a more tissue specific environment.² In contrast, a scaffold-free 3D culture is based on the concept that suspended cells from cell lines or fresh tissues reform 3D-tissues or spheroids by self-assembly of single cells if adhesion to a substrate is prevented.^{3–5} These cells adhere only to each other or to ECM molecules secreted by the cells. Despite the simple arrangement in the first instance, spheroids develop complex interactions, such as extensive cell–cell-contacts and -communication, a zonal architecture with gradients in oxygen, nutrients and pH, and polymerisation and remodelling of ECM molecules.^{6,7}

Well-established methods to generate spheroids are spinner flasks, liquid overlays (LO) and the hanging drop (HD) technique.^{8–11} Indeed the HD and LO techniques yield equally sized spheroids, but it remains a challenge to generate several thousand equally sized cell aggregates.^{12,13} Therefore, micro-structured surfaces with multiple microwells at the bottom of one single culture vessel represent an important alternative approach.¹⁴ Agarose is a low-cost, transparent and non-toxic hydrogel, that is permeable to gas and small biomolecules. Cells do not adhere to agarose, thus it favours cell to cell adhesion. Flat bottom agarose microwells for 3D cell culture are useful for drug testing,^{15,16} whereas pyramid-shaped agarose microwells allow stem cell aggregation and embryonic body formation.¹⁷

^a Department of Radiation Oncology, Medical Center – University of Freiburg, Germany. E-mail: andreas.thomsen@uniklinik-freiburg.de, per.lund@uniklinik-freiburg.de

^b German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany

^c Faculty of Medicine, University of Freiburg, Germany

^d Institute for Surgical Pathology, Medical Center – University of Freiburg, Germany

^e Comprehensive Cancer Center Freiburg, Medical Center – University of Freiburg, Germany

^f Freiburg Material Research Center and Institute for Macromolecular Chemistry, Department of Chemistry, University of Freiburg, Germany

^g Visceral and Transplantation Surgery, Department of Clinical Research, University of Bern, Switzerland

^h Institute for Medical Biometry and Statistics, Medical Center – University of Freiburg, Germany

ⁱ Department of Hematology/Oncology, Medical Center – University of Freiburg, Germany

^j Developmental Biology & Neurogenetics, Faculty of Biology, Technical University of Darmstadt, Germany

^k Department for Biophysics, GSI Helmholtz Center for Heavy Ion Research, Darmstadt, Germany

† Electronic supplementary information (ESI) available: Table S1, Fig. S1–S11 and Video S1. See DOI: 10.1039/c7lc00832e



produce a single cell suspension, counted in a haemocytometer and diluted according to the required cell count per ml. The pre-incubation medium was then removed and replaced with 9.5 ml of cell suspension containing 2.5% FCS. To harvest cell aggregates, the CAMA was turned upside down and centrifuged (1 min; $500 \times g$). After removal of the empty CAMA, cell aggregates were floating in the medium and collected with a serological pipette.

Readout and volumetry

To monitor volume changes of cell aggregates over time, plates with CAMA were scanned on a high-resolution flatbed scanner (CanoScan 9000F Mark II, Canon Inc.), using the transmitted light modus at 1200 dpi. Optionally, to enhance contrast in the final readout, viable cell aggregates inside CAMA were stained by incubating with 2 ml of DMEM containing 0.5 mg ml^{-1} MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide, Sigma) at 37°C for 3 h. The staining reaction was stopped by replacing the MTT solution with 2.5% acetic acid. From the central portion of each scan, a selection of 20 mm by 20 mm, comprising 100 or 400 microwells was cropped and stored as a greyscale TIF image. The projected area of each cell aggregate was measured using ImageJ image analysis software (NIH).

Volume calibration

A suspension of coloured polystyrene microbeads of $19.98 \mu\text{m}$ in diameter (microparticles GmbH, Germany) diluted in ethanol and thickened with 0.5% methylcellulose was loaded onto the CAMA and centrifuged to the bottom of the microwells. Images of microbead bulks in conical microwells were taken *via* a microscope camera and a flatbed scanner. Ethanol was substituted with coconut oil, which filled the space between the microbeads. When cooling to 4°C , the coconut oil solidified, which allowed retrieval of all microbeads from each microwell using a pointed blade. Microbead bulks from individual microwells were transferred onto microscopic glass slides, embedded with cedar wood oil and spread by gentle pressure onto the coverslip until the microbeads were in one optical plane. Absolute numbers of microbeads were counted by image analysis (ImageJ, NIH) and correlated with the volume calculated from the projected area of microbeads in the respective image.

Histology and immunohistochemistry

The CAMA was covered with 2% formalin solution in PBS overnight. To avoid loss of cell aggregates during further processing, microwells were sealed with warm 2.4% (w/v) low melting point agarose. Following paraffin embedding and casting into a block, $2 \mu\text{m}$ thick sections were cut and mounted onto slides. All slides were stored for two days at 58°C in a drying chamber, deparaffinized (using xylene) and hydrated (using ethanol). Subsequent slides were stained with haematoxylin and eosin (H&E) according to routine protocols or subjected to immunohistochemistry (IHC). IHC was

performed using ready-to-use antibodies for MIB-1 (monoclonal mouse anti-human antigen, Ki-67, Code IR626, MIB-1, Dako), pancytokeratin (monoclonal mouse anti-human antigen, Cytokeratin, Code M0821, MNF116, Dako), E-cadherin (monoclonal mouse anti-human antigen, E-cadherin, Code IR059, NCH-38, Dako), and vimentin (monoclonal mouse anti-human antigen, vimentin, Code IR630, V9, Dako).

For the detection of horseradish peroxidase EnVision Flex peroxidase-blocking reagent (DAKO, SM801), EnVision Flex + mouse (LINKER) (DAKO, K8021) and EnVision Flex/HRP (DAKO, SM802) were used. Before adding the coverslip, haematoxylin counterstaining was performed.

Live/dead staining

Cell aggregates in the CAMA were stained for 30 min at 37°C with $1 \mu\text{g ml}^{-1}$ fluorescein-diacetate (FDA) and $50 \mu\text{g ml}^{-1}$ propidium iodide (PI) in cell culture medium. After washing twice with medium, samples were examined with an inverted fluorescence microscope (IMT2 and scan[^]R, Olympus).

Treatment and irradiation of cell aggregates

Cisplatin was diluted in cell culture medium and added at a final concentration of $10 \mu\text{M}$. Irradiation was performed using ^{137}Cs in a Gammacell 40 Exactor (Best Theratronics, Canada) at a dose rate of 0.67 Gy min^{-1} .

Isolation of human mesenchymal stromal cells (hMSC)

The use of hMSCs from bone marrow for this study was approved by the ethics committee of the University Medical Center of Freiburg (vote number 212/16). The donor was informed about the study in detail, and provided written consent the day before tissue harvest. The identity of the donor was protected by the use of blinded probes. Primary hMSC were isolated from a bone marrow aspirate from a 43 year-old healthy male volunteer. Bone marrow aspirates of about 10 ml were drawn from the pelvic bone using a Jamshidi needle and a syringe pre-loaded with 1 ml of heparin solution. Aspirates were diluted with a 10-fold volume of media, so that bone marrow particles could be transferred into T75 flasks, in which 20–30 particles each were cultivated as explants in DMEM/F12 (Invitrogen) with 5% autologous human serum, insulin (2 IE l^{-1}), basic fibroblast growth factor (bFGF, 10 ng ml^{-1}), epidermal growth factor (EGF, 20 ng ml^{-1}), antibiotics, and $50 \mu\text{g ml}^{-1}$ ascorbic acid-2-phosphate (Sigma) at 37°C and 5% carbon dioxide. After 8–12 days, adherent hMSCs from explant cultures were sub-cultured and further expanded for another 2–3 weeks, including 1–2 passages. Human MSCs were functionally validated by the demonstration of adipogenic, osteogenic and chondrogenic differentiation (Fig. S1†).

Statistical analyses

The means of the measurements were compared using the unpaired Student's *t* test. Statistical analyses were performed with GraphPad Prism 6.0 (GraphPad Software, Inc., CA, USA).



Results and discussion

Physical properties of conical agarose microwell arrays

The CAMA, when fabricated as described (Fig. 1A), yields a reproducible geometry with defined distances between the

microwells. The CAMA is generated in two formats, with a microwell periodicity of either 1 or 2 mm, corresponding to 100 and 25 microwells per cm^2 . The microwell density differs with respect to the distance between the centres of the cones, while the size of the cones remains unaffected. Scanning




Fig. 1 Manufacturing and properties of the conical agarose microwell array (CAMA) (A) illustration of the CAMA fabrication process. The microwell array is milled into a polyoxymethylene (POM) block. The resulting master is covered with polydimethylsiloxane (PDMS) to generate a mould. The mould is cast with hot agarose, which is covered with a glass plate to generate a planar surface. Finally, the gelled agarose is removed from the mould resulting in the CAMA. (B) Scanning electron microscopy image of the milled POM masters and the PDMS moulds. (C) Profiles of two epoxy resin replicates made out of μ CT datasets. (D) Proportions of the microwell in the CAMA. The upper ($2w$) and the lower opening angle (2ϕ), the maximal ($2R$) and the minimal diameter ($2r$), the height of the cone (H) and the rounded bottom (h) are indicated. (E) Photography of the agarose array. (F) μ CT reconstruction of a CAMA with T47D spheroids in the microwells.



electron microscopy revealed the high accuracy in shape obtained by milling of the POM master structure and its subsequent moulding into PDMS (Fig. 1B). μ CT scans of the final CAMA and of epoxy resin replicates confirm the precision of the replica moulding process (Fig. 1C, Video S1†). Each microwell of the CAMA is designed as a truncated right circular cone. Measurements indicate the following approximate dimensions: the opening angle of the cone (2ϕ) is 20° , the microwell depth (H) is $1775\ \mu\text{m}$ with the lowest diameter ($2r$) between 237 and $255\ \mu\text{m}$, and the highest ($2R$) between 830 and $852\ \mu\text{m}$. The total volume of a single cone is $465 \times 10^6\ \mu\text{m}^3$. The apex is replaced by a rounded bottom of $40\ \mu\text{m}$ in height (h) at the site of truncation. The volume of this part is $1.68 \times 10^6\ \mu\text{m}^3$. At the upper end of the cone a linear slope formed by an opening angle (2ω) of about 115° serves to guide the cells into the microwell (Fig. 1D, Table S1†). The CAMA (Fig. 1E) is designed to fit into a 6-well plate. A μ CT reconstruction reveals the 3D shape and the arrangement of cell aggregates in the CAMA (Fig. 1F). The mechanical stability of the CAMA is not significantly altered after cell cultivation for 2 weeks (Fig. S2†).

The CAMA represents a technological advance for 3D cell culture due to the following features:

- Agarose hydrogels are low-adhesive materials that not only support scaffold-free cell aggregate formation, but also allow diffusion of nutrients, oxygen and catabolites,³¹ in contrast to synthetic polymers such as PDMS and polystyrene (Fig. S3†).

- CNC-milling was previously shown to result in high shape accuracy of cylindrical microwells in polystyrene dishes³² and, in combination with replica moulding, in polyethylene glycol (PEG).³³

- Contrary to cylindrical microwells, the conical shape centres the seeded cells, leading to formation of a single cell aggregate within each microwell.

- The conical microwells allow determination of the filling level corresponding to the cell aggregate volume using microscopic or scanner imaging in view of the rotational axis.

Remarkably, established precision methods such as photolithography and soft lithography usually result in perpendicular boundaries for microstructures,³⁴ while sloped or tapered boundaries are more difficult to generate. Because of this there have been few attempts to produce conical microwells to date. Laser ablation of a polyester surface bound to a glass substrate results in eccentric cones with non-uniform taper angles.²⁰ Despite optimized laser programming, power setting and writing speed, this method has failed to produce axisymmetrical cones. A femtosecond laser wet-etching process on silica glass produces microcones of defined angles with a diameter and height of 100 and $150\ \mu\text{m}$.³⁵ Therefore, we chose to mill the microwells into the material on a CNC machine, which has no size restrictions and allows fabrication of both cylindrical and tapered geometries by choice of the milling tool.³⁶ The production of a single master structure provides the opportunity to draw an almost unlimited number of PDMS moulds. This fabrication process ensures high

fidelity of shape for each microwell and each CAMA. This is crucial for an even cell distribution among the microwells.

Arrangement of cells in the CAMA

We observe that cells distributed onto the CAMA sediment into the microwells within 2 h to 4 h and form conical aggregates. During cultivation the cells either remain as conical aggregates or form spheroids. In both cases the volume of each aggregate is proportional to the projected area (Fig. 2A) and calculated after scanning (Fig. S4†) using the formulas as indicated (Fig. S5†). In contrast to cylindrical microwells the projected area seen from the bottom in conical microwells increases with the filling level (Fig. S6†). In order to validate that the measured volume is proportional to a given number of physical entities of a defined volume, we loaded microbeads onto the CAMA. Linear regression analysis shows that the calculated volume correlates with the number of microbeads loaded ($r^2 = 0.99$) (Fig. 2B). Equally, the number of cells seeded per microwell significantly correlates with the volume of the cell aggregates ($r^2 = 0.94$ (HT-29); $r^2 = 0.99$ (Panc-1); $r^2 = 0.96$ (MDA-MB-231)) (Fig. 2C). A narrow distribution of cell aggregate volumes in between the individual microwells is seen when a defined cell number is loaded (Fig. 2D).

Several cell lines have been tested in the CAMA to determine their 3D-aggregation and growth properties (Table 1).

CAMA not only shares the benefit of the spheroid model in which volumes of individual spheroids may easily be determined from the diameter or projected area,¹¹ but extends this feature to non-spheroid forming cell types. We observe a linear correlation between the loaded cell number and the volume measured for spheroid forming (HT-29, Panc-1) and non-spheroid forming cell aggregates (MDA-MB-231). CAMA generates homogeneously sized and shaped cell aggregates. Limited to spheroid forming cells, this has been shown in another microwell device approach.³⁷ Cell aggregates of irregular shape require more complex imaging and calculation modalities to approximate the volume,³⁸ which hampers high-throughput measurement of cell aggregates. Importantly, a considerable fraction of cancer cell lines relevant for cancer research fails to form spheroids.²⁹ CAMA overcomes this limitation by shaping these cells into a conical cell aggregate, which enables volume determination regardless of their capacity for spheroid formation. In addition, deep microwells with a high-aspect ratio such as CAMA provide the advantage that cells or cell aggregates remain trapped. The cells are not easily lost when medium is exchanged or the array is moved.

Histological processing

In this work, we present a simple method for histological processing of spheroids and cell aggregates in the CAMA (Fig. 3A, Fig. S7†) as described in Materials & methods. The arrangement of the cells is revealed by H&E-staining, whereas IHC shows cell line specific marker profiles (Fig. 3B). Breast cancer associated fibroblasts (BrCa-aF) were negative for






Fig. 2 Volume determination and calibration of cellular aggregates in the CAMA (A) the measuring cup principle for determination of spheroid (upper row) and cell aggregate (lower row) volume in the CAMA. The diagram illustrates the increase in volume during cultivation, corresponding to the projected area seen from the bottom. Representative samples of spheroids of T47D breast and conical cell aggregates of MIA PaCa-2 pancreatic cancer cells are shown after harvesting. (B) Calibration of the volume to microbead numbers. A total of 20 542 microbeads was loaded onto the CAMA, centrifuged, scanned and photographed for the microwell in its defined position. From each microwell the microbeads were extracted, counted and correlated to the calculated aggregate volume. (C) Calibration of cell aggregate volume against cell number. Three cell lines were seeded at defined cell numbers 6 h before scanning. Regression curves are indicated. Each data point represents the mean of 81 replicates. Representative data for one out of two experiments are shown. (D) Dot plot for volume distribution of MDA-MB-231 cell aggregates seeded at defined numbers (upper row). Corresponding single cell aggregates and scans of CAMA regions are shown (lower row).

staining with the epithelium-specific marker pan-cytokeratin and positive for vimentin. In contrast, all epithelium-derived cancer cell lines were pan-cytokeratin positive. Notably, BT-

Table 1 Cell aggregate type formation of human cells in the CAMA

Cell types	Abbreviation	3D shape
<i>Primary cells</i>		
Entity		
Adipose tissue	<i>Adipo-MS*</i>	⊙↓
Bone marrow stroma	<i>BM-MS*</i>	⊙↓
Breast cancer associated fibroblasts	<i>BrCa-aF**</i>	⊙↓
Cord blood hematopoietic stem cells	<i>CD34+ HSC***</i>	⊙
<i>Non cancer cell lines</i>		
Entity		
Lung	<i>BEAS-2B</i>	⊙
	<i>NBEC</i>	⊙
	<i>FBEC</i>	⊙
<i>Cancer cell lines</i>		
<i>Tumour entity</i>		
Breast	<i>BT-474</i>	⊙
	<i>BT-549</i>	⊙
	<i>MCF7</i>	⊙
	<i>MDA-MB-231</i>	⊙
	<i>T47D</i>	⊙
Colon	<i>HT-29</i>	⊙
Epidermoid carcinoma	<i>A431</i>	⊙↓
Glioblastoma	<i>GBM4****</i>	⊙
	<i>U251</i>	⊙
Hypopharynx	<i>FaDu</i>	⊙
Liver	<i>Hep3B</i>	⊙
	<i>HepG2</i>	⊙
	<i>Huh-7*****</i>	⊙
	<i>SNU-449</i>	—
Lymphoma	<i>U937</i>	⊙
Multiple myeloma	<i>L363</i>	⊙
	<i>U266</i>	⊙
Pancreas	<i>MIA PaCa-2</i>	⊙
	<i>Panc-1</i>	⊙
	<i>PSN-1</i>	⊙
Prostate	<i>LNCap</i>	⊙
	<i>PC-3</i>	⊙

It is indicated whether the cell lines grow as classical spheroids (⊙), cone-shaped aggregates (⊙↓) or loose cell clusters (⊙). SNU-449 do not survive —. Spheroids that do not proliferate after aggregation are marked ⊙↓. *Adipo-MS and BM-MS were established in our lab. **BrCa-aF were kindly provided by J. Maurer (Dept. of Molecular Oncology, Freiburg); ***CD34+ HSC by M. Erlacher (Dept. of Pediatrics, Freiburg); ****GBM4 by E. Firat (Dept. of Radiation Oncology, Freiburg) and *****Huh-7 by M. Nassal (Dept. of Gastroenterology, Freiburg). The remaining cell lines are from ATCC (American Tissue Culture Collection).

474 exhibits a central necrotic zone, while proliferating (MIB-1-positive) cells dominate in the periphery of the tumour spheroids. This observation is consistent with the pattern expected for tumour spheroids.⁸






Fig. 3 Histological processing of 3D cell cultures in CAMA (A) diagram of the preparation of histological slides. Formalin-fixed microwell arrays are sealed with low melting point (LMP) agarose. Following automated dehydration and paraffin infiltration, the CAMA is turned upside down, embedded by addition of paraffin and mounted onto a cassette. Sections of 2 µm are prepared using a microtome for subsequent standard staining procedures. (B) Histology of breast cancer associated fibroblasts (BrCa-aF), BT-474 and MDA-MB-231 breast cancer and MIA PaCa-2 pancreatic cancer cells with H&E and immunohistochemical staining for MIB-1, pancytokeratin, E-cadherin and vimentin.

The size of the spheroids makes them susceptible to loss or damage during histological processing.³⁹ Available protocols that are adapted to manual fixation dehydration and embedding of spheroids have been shown to result in good preservation of morphology. However, such methods comprise several manual steps and are not easily adapted to automated sample processing.^{40,41} In the CAMA the cell aggregates can be subjected to standard histological processing, because the microwells are sealed with a second layer of agarose to immobilise the cells. Subsequent paraffin embedding and slice preparation follows established procedures. Therefore, CAMA facilitates histological preparation of 3D cell cultures.

Modulation of microwell spacing affects cell growth

The distance between the microwells is 1 mm with 100 microwells per cm² in the 1 × 1 CAMA, and 2 mm with 25 microwells per cm² in the 2 × 2 CAMA, respectively. To determine the effect of microwell spacing on cell growth we compared the increase of MIA PaCa-2 cell aggregate volumes in both formats after seeding identical cell numbers per microwell. The growth of the cell aggregates is significantly enhanced in the 2 × 2 format (Fig. 4A and B). IHC staining of the proliferation marker MIB-1 reveals a higher fraction of proliferating cells in the 2 × 2 format (Fig. 4C).

The increase in distance between spheroids results in a gain of culture medium available per cell aggregate. This may explain the correlation of distance between spheroids and

spheroid volume that has been reported previously.⁴² The advantage of a high density of microwells per cm² is the high




Fig. 4 Effect of microwell spacing on cell aggregate growth comparison of MIA PaCa-2 pancreatic cancer cell aggregate growth in the 1 × 1 and 2 × 2 CAMA. (A) Time-dependent increase in cell aggregate volume with (B) corresponding fluorescence-microscopy images after fluorescein diacetate- and (C) MIB-1 immunohistochemical staining; d = days in culture. Initially seeded at d0: 1000 cells per microwell. Data are means ± SEM. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ($n = 2$).



number of replicates, with the disadvantage of rapid shortage of nutrients and accumulation of waste products (Fig. S8†). Consequently, for seeding >1000 cpm (cells per microwell) or experiments that require cell cultivation for several weeks, the 2×2 CAMA is recommended. As metabolic demands and proliferation rates may greatly differ among cell lines, metabolic measures may be performed to further adjust seeding densities. Indeed, it is a unique feature of the CAMA that microwell spacing is variable, while the volume of the microwell remains unchanged. Therefore, it differs from previously designed 3D-microwell arrays where an increase in microwell spacing is coupled to an increase in microwell diameter.^{18,43}

The decrease in MIB-1 expression from the periphery to the centre of the MIA PaCa-2 cell aggregates (Fig. 4C) corresponds to an outer proliferation zone that can be distinguished from a central quiescent zone. This arrangement is caused by diffusion gradients and occurs in tumours *in vivo*.⁴⁴ This has so far been shown in classical spheroids,⁴⁵ but not in aggregates of non-spheroid forming cells such as MIA PaCa-2. Therefore, this finding indicates that CAMA allows non-spheroid forming cells to grow as 3D aggregates with an *in vivo*-like microenvironment.

CAMA in comparison to the hanging drop and liquid overlay methods

We compared the growth of the spheroid forming cell line T47D and the non-spheroid forming cell line MIA PaCa-2 using.

Hanging drop (HD), liquid overlay (LO) and CAMA, in order to determine differences in cell proliferation and cell density. T47D show similar spheroid formation in HD, LO and CAMA (data not shown). In contrast, MIA PaCa-2 form stable cell aggregates in CAMA, loose cell aggregates in LO and only small, dispersed aggregates in HD (Fig. 5A). While the ratio of MIB-1-positive cells is slightly decreased in HD compared to LO and CAMA (Fig. 5B and C), the minor axis diameter is significantly increased in the CAMA (Fig. 5D). MIA PaCa-2 cell aggregates cultivated in CAMA grow to higher cell densities compared to LO, thereby covering a smaller area. In HD the area is not measured due to cell dispersion. Notably, the volume of the cell aggregates can be determined only in CAMA (Fig. 5E).

In clinical oncology tumour size is the central parameter for evaluation of treatment response⁴⁶ and is similarly considered to be a superior read-out in 3D-cell culture assays, compared to metabolic measurements.^{47,48} CAMA meets this demand by enabling non-destructive, repeatable volume determination over several weeks (Fig. S9†).

Treatment and irradiation of cell aggregates in the CAMA

CAMA allows monitoring dose-dependent effects of complex treatments using cell aggregate volume as readout. For example, in radiation oncology chemotherapy is frequently combined with irradiation. Combination of cisplatin with irradiation reveals a radiosensitising effect on MIA PaCa-2 cell aggregates, reaching its maximum at 5 Gy (Fig. 6). MIA PaCa-




Fig. 5 MIA PaCa-2 cell aggregate growth in hanging drop (HD), liquid overlay (LO) and the conical agarose microwell array (CAMA) (A) images of single cell aggregates during cultivation in HD, LO or CAMA. Additionally, fluorescence microscopy images of FDA- (green/viable cells) and PI- (red/dead cells) stained aggregates are shown. (B) MIB-1 IHC, (C) ratio of MIB-1 positive cells and (D) minor axis diameter of single cell aggregates after cultivation in HD, LO or CAMA for 96 h. Each data point represents the mean of at least 20 replicates. (E) Time-dependent increase in cell aggregate area (LO, CAMA) and volume (CAMA). Each data point represents the mean of at least 20 replicates. Data are means $\pm$ SEM, ($n = 2$).

2 has an undifferentiated, E-cadherin-negative, non-cohesive phenotype⁴⁹ and does not form spheroids. Importantly, MIA PaCa-2 belongs to a group of non-spheroid, yet cell aggregate forming tumour cells that could not be analysed with hitherto existing culture methods.

In comparison to high-throughput 3D assays that allow screening of 384 to 1536 conditions per plate, one plate loaded with the CAMA is limited to a screen of 6 to 24






Fig. 6 Combined chemotherapy and irradiation of cancer cell aggregates in CAMA. MIA PaCa-2 pancreatic cancer cell aggregates were incubated 48 h after seeding with 10 μ M cisplatin (CP) and irradiated 6 h later. CP was removed after another 18 h. A scatter plot analysis with the means $\pm$ SD is shown (blue spots = irradiated at the dose indicated; red spots = combined irradiation and treatment with CP). The bar represents the mean of at least 200 replicates. Statistical comparison were done for each pair of CP treated and untreated sample at equal irradiation dose using Student's unpaired *t*-test assuming a Gaussian distribution. n.s. (not significant), $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. One representative out of three experiments is shown together with the corresponding CAMA scans.

conditions. Nevertheless, CAMA offers the advantage of screening hundreds of replicates per treatment condition. This ensures high statistical significance. Furthermore, in experiments where a heterogeneous treatment response is expected, a high number of replicates is essential to yield significant results and to eliminate outliers. In particular, this is the case in irradiation experiments, where stochastic events are involved and the fractions of treatment responders and non-responders needs to be identified based on a high number of replicates (Fig. S10†). In particular, when cells are derived from a tumour mass that consists of genetically unstable and therefore heterogeneous populations the treatment response may vary considerably.

Co-culture in CAMA

The interaction of distinct cell types determines tissue development and plays a major role in disease biology. The fate of cancer cells depends largely on their interactions with different cell types in the tumour microenvironment.⁵⁰ Special emphasis has been put on investigating the interaction between stromal and cancer cells.^{51,52} Two classical approaches in co-culture experiments have been established: contact (direct) and distance (indirect) co-culture. However, the vast majority of co-culture experiments are performed in 2D systems.

Importantly, CAMA can easily be applied to perform both contact and distance 3D co-culture experiments (Fig. 7A). We have found that the growth and absolute number of spher-

oids formed is significantly enhanced in T47D breast cancer cells in contact and distance co-culture with human MSCs as compared to monoculture (Fig. 7B). The conical cell aggregate forming MIA PaCa-2 pancreatic cancer cells were co-cultured with human MSCs under the same conditions, but no changes in growth were observed compared to monoculture (data not shown).

The PREDECT (New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours) consortium aims to improve preclinical methods, including *in vitro* 3D organotypic (co-) cultures that permit greater predictability of drug efficacy, with the goal of studying samples of tumour patient cohorts. In this context 2D and 3D models of stromal cells co-cultured with breast, prostate and lung cancer cell lines were compared. Cells were tested for drug sensitivity as 2D monolayers, as spheroids in suspension and spheroids embedded in defined substrates.⁵³ Co-culture experiments in CAMA upgrade the portfolio of available methods, eliminating the effects on co-culture due to exogenous factors such as those found in Matrigel. In distance co-culture the spatial separation of stromal cells (adherent to the culture dish) from the tumour cells (in the microwells) allows selective treatment of one cell type. Thus, changes in volume can be attributed to the treatment of one cell type. In contact co-




Fig. 7 3D co-culture in the CAMA (A) diagram: For contact co-culture the distinct cell types are seeded together into the CAMA. For distance co-culture one cell type is seeded into the CAMA, then the CAMA is placed on the monolayer composed of another cell type. Examples shown are cancer (yellow) and mesenchymal stromal cells (MSC; violet). (B) Effect of human MSC on growth and spheroid formation of T47D breast cancer cells in contact and distance co-culture. Cell seeding: T47D (10 cells per microwell (cpm)); MSC for contact co-culture (10 cpm); MSC for distance co-culture (10^3 cells per cm^2) on the culture dish. Volume determination was done at d20 ($n = 3$). An image of 4 spheroids (left) and of a CAMA scan (right) is shown. Data are means $\pm$ SEM. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.



cultures the situation is more intricate. Here both cell types are affected by the treatment in the first instance, so that a volume change could be due to effects on stromal or tumour cells or both. Yet we found that hMSCs do not proliferate under contact co-culture conditions (Fig. S11†). Therefore, in this case a volume change can be attributed to the tumour cells. However, even in cases when two proliferating cell types are seeded into contact co-culture, the CAMA enables IHC staining to distinguish the two cell types and to analyse underlying mechanisms.

Conclusions

In summary, CAMA supports the formation and long-term 3D-culture of cell aggregates in a scaffold-free system. The CAMA method is unique because the compact, conical shape of the wells allows them to function as a form of “measuring cup”, allowing easy and accurate quantification of cell aggregate volume over time. The rugged design of the agarose hydrogel array results in high reproducibility. This allows its introduction into standard cell culture laboratories, where it is can be used for high-throughput applications. Importantly, CAMA is not limited to spheroid forming cells, allowing this platform to extend the number of cell types that can be tested in a scaffold-free 3D mono- and co-culture system. It is noteworthy that monoculture experiments can easily be translated into co-culture experiments. Analyses include a variety of applications such as the measurement of dose-response drug and irradiation kinetics and a simple, efficient procedure for preparation of histological and immunohistological slides.

Conflicts of interest

A patent application covering this work is published as EP 2917326 A1 and WO 2014072432 A1. ART, NN and GN are named as inventors in the patent application. In case a patent should be granted and lead to a commercial product (which is currently considered for distribution under the name of “CoSeedis”), it is anticipated that the University of Freiburg will receive license fees, of which shares would be distributed to the inventors and to the Department of Radiation Oncology. The remaining authors have no conflicts to declare.

Acknowledgements

This work was supported by the Dr. med. h. c. Erwin Braun Foundation. The authors wish to thank Markus Kühs for preparation and staining of paraffin sections, Dr. Lukas Konstantinidis for help with material testing, Dr. Anne-Marie Luchtenborg and Dr. Horst Ibelgauf for discussions.

References

- 1 V. E. Santo, S. P. Rebelo, M. F. Estrada, P. M. Alves, E. Boghaert and C. Brito, *Biotechnol. J.*, 2017, **12**, 1600505.
- 2 E. Carletti, A. Motta and C. Migliares, *Methods Mol. Biol.*, 2010, **695**, 17–39.
- 3 W. Mc Limans, E. V. Davis, F. L. Glover and G. W. Rake, *J. Immunol.*, 1957, **79**, 428–433.
- 4 J. M. Kelm, L. M. Ittner, W. Born, V. Djonov and M. Fussenegger, *J. Biotechnol.*, 2006, **121**, 86–101.
- 5 M. A. Kinney, C. Y. Sargent and T. C. McDevitt, *Tissue Eng., Part B*, 2011, **17**, 249–262.
- 6 J. Friedrich, R. Ebner and L. A. Kunz-Schughart, *Int. J. Radiat. Biol.*, 2007, **83**, 849–871.
- 7 E. Fennema, N. Rivron, J. Rouwkema, C. van Blitterswijk and J. de Boer, *Trends Biotechnol.*, 2013, **31**, 108–115.
- 8 R. M. Sutherland, B. Sordat, J. Bamat, H. Gabbert, B. Bourrat and W. Mueller-Klieser, *Cancer Res.*, 1986, **46**, 5320–5329.
- 9 J. M. Kelm, N. E. Timmins, C. J. Brown, M. Fussenegger and L. K. Nielsen, *Biotechnol. Bioeng.*, 2003, **83**, 173–180.
- 10 A. Nagelkerke, J. Bussink, F. C. G. J. Sweep and P. N. Span, *Anal. Biochem.*, 2013, **437**, 17–19.
- 11 B. Rodday, F. Hirschhaeuser, S. Walenta and W. Mueller-Klieser, *J. Biomol. Screening*, 2011, **16**, 1119–1124.
- 12 A. Ivascu and M. Kubbies, *J. Biomol. Screening*, 2006, **11**, 922–932.
- 13 D. R. Albrecht, G. H. Underhill, T. B. Wassermann, R. L. Sah and S. N. Bhatia, *Nat. Methods*, 2006, **3**, 369–375.
- 14 Y. Miyamoto, M. Ikeuchi, H. Noguchi, T. Yagi and S. Hayashi, *Cell Medicine*, 2015, **8**, 47–56.
- 15 X. Gong, C. Lin, J. Cheng, J. Su, H. Zhao, T. Liu, X. Wen and P. Zhao, *PLoS One*, 2015, **10**, e0130348.
- 16 Y. Tang, J. Liu and Y. Chen, *Microelectron. Eng.*, 2016, **158**, 41–45.
- 17 J. Dahlmann, G. Kensah, H. Kempf, D. Skvorc, A. Gawol and D. A. Elliott, *et al.*, *Biomaterials*, 2013, **34**, 2463–2471.
- 18 A. P. Napolitano, D. M. Dean, A. J. Man, J. Youssef, D. N. Ho and A. P. Rago, *et al.*, *BioTechniques*, 2007, **43**, 496–500.
- 19 X. Xu, W. Wang, K. Kratz, L. Fang, Z. Li, A. Kurtz, N. Ma and A. Lendlein, *Adv. Healthcare Mater.*, 2014, **3**, 1991–2003.
- 20 S. Selimović, F. Piraino, H. Bae, M. Rasponi, A. Redaelli and A. Khademhosseini, *Lab Chip*, 2011, **11**, 2325–2332.
- 21 J. Carlsson and J. M. Yuhas, *Recent Results Cancer Res.*, 1984, **95**, 1–23.
- 22 B. Patra, C. C. Peng, W. H. Liao, C. H. Lee and Y. C. Tung, *Sci. Rep.*, 2016, **6**, 21061.
- 23 K. C. Hribar, D. Finlay, X. Ma, X. Qu, M. G. Ondeck, P. H. Chen and F. Zanella, *et al.*, *Lab Chip*, 2015, **15**, 2412–2418.
- 24 Y. C. Chen, X. Lou, Z. Zhang, P. Ingram and E. Yoon, *Sci. Rep.*, 2015, **5**, 12175.
- 25 G. H. Lee, Y. E. Park, M. Cho, H. Park and J. Y. Park, *Lab Chip*, 2016, **16**, 3565–3575.
- 26 A. Kang, H. I. Seo, B. G. Chung and S. H. Lee, *Nanomedicine*, 2015, **11**, 1153–1161.
- 27 F. Madoux, A. Tanner, M. Vessels, L. Willetts, S. Hou, L. Scampavia and T. P. Spicer, *SLAS Discov.*, 2017, **22**, 516–524.
- 28 K. Halfter and B. Mayer, *Biotechnol. J.*, 2017, **12**, 1600295.
- 29 J. Friedrich, C. Seidel, R. Ebner and L. A. Kunz-Schughart, *Nat. Protoc.*, 2009, **4**, 309–324.
- 30 G. Benton, I. Arnaoutova, J. George, H. K. Kleinman and J. Koblinski, *Adv. Drug Delivery Rev.*, 2014, **79–80**, 3–18.



- 31 M. Sittinger, J. Bujia, W. W. Minuth, C. Hammer and G. R. Burmester, *Biomaterials*, 1994, **15**, 451–456.
- 32 J. Fukuda and K. Nakazawa, *Tissue Eng.*, 2005, **11**, 1254–1262.
- 33 K. Nakazawa, Y. Yoshiura, H. Koga and Y. Sakai, *J. Biosci. Bioeng.*, 2013, **116**, 628–633.
- 34 J. C. Love, J. L. Ronan, G. M. Grotenbreg, A. G. van der Veen and H. L. Ploegh, *Nat. Biotechnol.*, 2006, **24**, 703–707.
- 35 H. Bian, Q. Yang, F. Chen, H. Liu, G. Du, Z. Deng, J. Si, F. Yun and X. Hou, *Mater. Sci. Eng., C*, 2013, **33**, 2795–2799.
- 36 D. J. Guckenberger, T. E. de Groot, A. M. Wan, D. J. Beebe and E. W. Young, *Lab Chip*, 2015, **15**, 2364–2378.
- 37 H. C. Moeller, M. K. Mian, S. Shrivastasa, B. G. Chung and A. Khademhosseini, *Biomaterials*, 2008, **29**, 752–763.
- 38 M. Zanoni, F. Piccinini, C. Arienti, A. Zamagni, S. Santi, R. Polico, A. Bevilacqua and A. Tesei, *Sci. Rep.*, 2016, **6**, 19103.
- 39 T. R. Olsen, B. Mattix, M. Casco, A. Herbst, C. Williams, A. Tarasidis, L. Jenkins, C. L. McMahan, D. Simionescu, R. P. Visconti and F. Alexis, *J. Histotechnol.*, 2014, **37**, 138–142.
- 40 P. K. Kabadi, M. M. Vantangoli, A. L. Rodd, E. Leary, S. J. Madnick, J. R. Morgan, A. Kane and K. Boekelheide, *BioTechniques*, 2015, **59**, 279–286.
- 41 J. Kang, D. W. Lee, H. J. Hwang, S. E. Yeon, M. Y. Lee and H. J. Kuh, *Lab Chip*, 2016, **16**, 2265–2276.
- 42 H. Hardelauf, J. P. Frimat, J. D. Stewart, W. Schormann, Y. Y. Chiang, P. Lampen, J. Franzke, J. G. Hengstler, C. Cadenas, L. A. Kunz-Schughart and J. West, *Lab Chip*, 2011, **11**, 419–428.
- 43 M. D. Ungrin, C. Joshi, A. Nica, C. Bauwens and P. W. Zandstra, *PLoS One*, 2008, **3**, e1565.
- 44 C. Carmona-Fontaine, M. Deforet, L. Akkari, C. B. Thompson, J. A. Joyce and J. B. Xavier, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **114**, 2934–2939.
- 45 D. R. Grimes, P. Kannan, A. McIntyre, A. Kavanagh, A. Siddiky, S. Wigfield, A. Harris and M. Partridge, *PLoS One*, 2016, **11**, e0153692.
- 46 E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, *Eur. J. Cancer*, 2009, **45**, 228–247.
- 47 D. P. Ivanov, T. L. Parker, D. A. Walker, C. Alexander, M. B. Ashford, P. R. Gellert and M. C. Garnett, *PLoS One*, 2014, **9**, e103817.
- 48 M. Jennewein, M. Bubel, S. Guthörl, W. Metzger, M. Weigert, T. Pohlemann and M. Oberringer, *Cell Tissue Res.*, 2016, **365**, 279–293.
- 49 J. M. Winter, A. H. Ting, F. Vilardell, E. Gallmeier, S. B. Baylin, R. H. Hruban, S. E. Kern and C. A. Iacobuzio-Donahue, *Clin. Cancer Res.*, 2008, **14**, 412–418.
- 50 M. Pickup, S. Novitskiy and H. L. Moses, *Nat. Rev. Cancer*, 2013, **13**, 788–799.
- 51 C. J. Olsen, J. Moreira, E. M. Lukanidin and N. S. Ambartsumian, *BMC Cancer*, 2010, **10**, 444.
- 52 F. Ozawa, K. Ino, T. Arai, J. Ramon-Azcon, Y. Takahashi, H. Shiku and I. Matsue, *Lab Chip*, 2013, **13**, 3128–3135.
- 53 K. Stock, M. F. Estrada, S. Vidic, K. Gjerde, A. Rudisch, V. E. Santo and M. Barbier, *et al.*, *Sci. Rep.*, 2016, **6**, 28951.

